Health Care Select Sector (XLV)

Latest stories mapped to XLV

• 2026-09-18 10 large and mega-cap U.S. healthcare stocks with the weakest momentum grades
• 2026-09-18 Ionis stock falls 44% as InvestingPro Fair Value predicted overvaluation
• 2026-09-18 Exclusive-Anthropic quietly sets up biology lab as it ramps AI drug program
• 2026-09-18 Why is Dr Reddy’s Laboratories stock gaining today?
• 2026-09-18 Medical AI has a proof problem
• 2026-09-17 Ultragenyx sets $3.95 million price for rare disease gene therapy
• 2026-09-17 Biogen reports trial results for kidney disease drug in adolescents
• 2026-09-17 FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
• 2026-09-17 Ultragenyx wins FDA approval for pediatric gene therapy for Sanfilippo syndrome
• 2026-09-17 Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
• 2026-09-17 Medicare changes coming in 2027: What to know before open enrollment
• 2026-09-17 Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?
• 2026-09-17 Johnson & Johnson at deutsche bank healthcare summit: growth outlook lifts
• 2026-09-17 BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs
• 2026-09-17 GRAIL rated new Sector Perform at RBC ahead of FDA AdCom on Galleri
• 2026-09-17 Boston Scientific downgraded at Citi on increasing competition, cyberattack fallout
• 2026-09-17 Electra Therapeutics IPO expected to price above midpoint
• 2026-09-17 Novo hemophilia therapy granted EU recommendation
• 2026-09-17 Medtronic (MDT) Raises its Outlook Again as Heart Device Demand Keeps Climbing
• 2026-09-17 TD Cowen maintains Boston Scientific stock rating after cyberattack